

INVIVO

THERAPEUTICS™

InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference

September 11, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 11, 2020-- **InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV)**, a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for Wednesday, September 16, 2020 at 11:00 am Eastern Time. A live webcast will be available at <https://wsw.com/webcast/hcw7/nviv/1631915>. Dr. Toselli will discuss recent company updates, including updates related to the Company's ongoing INSPIRE 2.0 Study for acute thoracic SCI. In addition to the presentation, Dr. Toselli will also be available for one-on-one meetings with investors who are registered to attend the conference, which runs from September 14 – 16, 2020.

About InVivo Therapeutics

InVivo Therapeutics (Nasdaq: NVIV) is a clinical-stage biotechnology company focused on redefining the treatment of spinal cord injury. InVivo's proprietary and investigational Neuro-Spinal Scaffold, based on technology licensed from Robert S. Langer's lab at Massachusetts Institute of Technology, is in pivotal clinical studies for acute spinal cord injury. The company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200911005057/en/): <https://www.businesswire.com/news/home/20200911005057/en/>

Investor Contact:

Bret Shapiro, Managing Partner
CORE IR
brets@coreir.com
(516) 222-2560

Source: InVivo Therapeutics Holdings Corp.